International law firm Bird & Bird has advised Proteome Sciences plc on its placing, subscription and heavily oversubscribed retail offer.
Proteome Sciences plc is a UK-based leader in applied proteomics and peptidomics, providing contract research services focused on the identification, validation, and application of protein biomarkers for pharmaceutical, biotech and academic clients. The company’s platforms play an increasingly important role in supporting drug discovery, translational research and biomarker-driven development strategies.
This transaction was significant in securing essential working capital to support the continued development and commercial progression of the company’s TMT® tags and to prepare for the launch and commercialisation of a new range of DXT isotopic plex tags. The proceeds will also enable Proteome Sciences to advance its ‘Solvent Shift’ chemoproteomic workflows and invest in the expansion of both its team and operational capacity at its San Diego facility, enhancements that will help meet growing demand from its global customer base.
The Bird & Bird team was led by Corporate partner Fiona McFarlane, supported by associates Amy Donlevey, Carissa Najafian and trainee solicitor Esha Makwana.
Lead partner on the transaction, Fiona McFarlane, commented: “We’re delighted to have supported Proteome Sciences on this important fundraise, which will enable the next phase of innovation and the launch and commercialisation of a new range of tags. Their technology plays a vital role in advancing biomarker discovery globally and this transaction reflects the continued momentum we’re seeing across the Life Sciences sector. With one of Bird & Bird’s longstanding focus being supporting Life Science businesses, we’re proud to have worked with the Proteome Sciences team to help position the company for its next stage of growth.”
